Novel RNA interference agents improve lipid profiles in healthy volunteers

Two novel RNA interference agents, one targeting apolipoprotein C-III and one targeting angiopoietin-like protein 3, improved various lipid parameters in early studies with healthy volunteers, according to new data presented at the American Heart Association Scientific Sessions. One agent targeting apolipoprotein C-III (ARO-APOC3, Arrowhead) was associated with reductions in serum APOC3 and improvements in other lipids, while another agent targeting ANGPTL3 (ARO-ANG3, Arrowhead Pharmaceuticals) was associated with reductions in ANGPTL3 and improvements in other lipids, researchers reported.